APARTSIN, K.A., N. A. SVERDLOVA, V. V. KIREEVA, Abanoub RIAD a Miloslav KLUGAR. International COVID-19 Vaccines Safety Tracking Study (CoVaST-RU): Participation of the Russian Federation. Profilakticheskaya meditsina. 2021, roč. 24, č. 12, s. 31-40. ISSN 2305-4948. Dostupné z: https://dx.doi.org/10.17116/profmed20212412131.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název International COVID-19 Vaccines Safety Tracking Study (CoVaST-RU): Participation of the Russian Federation
Autoři APARTSIN, K.A., N. A. SVERDLOVA, V. V. KIREEVA, Abanoub RIAD (818 Egypt, domácí) a Miloslav KLUGAR (203 Česká republika, domácí).
Vydání Profilakticheskaya meditsina, 2021, 2305-4948.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30304 Public and environmental health
Stát vydavatele Rusko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Kód RIV RIV/00216224:14110/21:00124034
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.17116/profmed20212412131
Klíčová slova anglicky COVID-19; vaccination; side effects; Gam-COVID-Vac (Sputnik V); CoviVac; Sputnik Light
Štítky rivok
Příznaky Mezinárodní význam
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 17. 5. 2022 13:04.
Anotace
Side effects associated with COVID-19 vaccines play a crucial role in the public decision regarding the importance and necessity of vaccination. Objective. Global active surveillance of the safety and efficacy of COVID-19 vaccines. The importance of participation of the Russian Federation is determined by obtaining data on the efficacy and safety of vaccines approved for use in the country, such as GamCOVID-Vac (Sputnik V), EpiVacCorona, CoviVac, and Sputnik Light, and comparing them with vaccines used abroad. Material and methods. The international study includes 3 phases to evaluate vaccine efficacy and safety in target populations. The first phase will study adverse reactions associated with primary vaccination, the second phase will investigate the side effects of booster doses, and the third phase will assess the long-term safety and efficacy of COVID-19 vaccines. Validated electronic questionnaires completed by the target population will be used for data collection. Expected results. The study will provide evidence-based data on the efficacy and safety of domestic vaccines in comparison with foreign vaccines. The study protocol is registered at ClinicalTrials.gov under the identifier NCT04834869. Russian Federation (CoVaST-RU) is included in the study on 26 July 2021.
VytisknoutZobrazeno: 24. 6. 2024 23:16